Showing results (371-380 of 400) with videos related to

Sort By:
Pageof 40
Infection and Immunity|February 7, 1998
Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosyA H Zea, M T Ochoa, P Ghosh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 1992
Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cureD L Longo, P L Duffey, R C Young, et al.
Blood|October 24, 1997
Antitumor effects of nonconjugated murine Lym-2 and human-mouse chimeric CLL-1 monoclonal antibodies against various human lymphoma cell lines in vitro and in vivoS Funakoshi, A Hirano, M Beckwith, et al.
Blood|April 27, 1999
Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligandA Hirano, D L Longo, D D Taub, et al.
Blood|April 1, 1997
Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunityM L Saxton, D L Longo, H E Wetzel, et al.
The New England Journal of Medicine|November 1, 1984
Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferonK A Foon, S A Sherwin, P G Abrams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2B D Curti, D L Longo, A C Ochoa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 1995
Alterations in T cell receptor and signal transduction molecules in melanoma patientsA H Zea, B D Curti, D L Longo, et al.
Cancer Research|April 1, 1989
Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanomaR L Miller, R G Steis, J W Clark, et al.
Journal of the National Cancer Institute|April 18, 1990
Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trialR G Steis, L A VanderMolen, D L Longo, et al.
Pageof 40